A CRISPRko screen to understand enzalutamide resistance in prostate cancer CWR-R1 and 22Rv1 cells and focusing on kinases revealed the role of activated BRAF [143] and of CK1α [144]. Here, CSNK1A1 is linked to prostate carcinoma.